生物活性: Volagidemab is an antagonistic glucagon receptor (GCGR) monoclonal antibody (mAb). Volagidemab can be used in the research of type 1 diabetes (T1D).
体内研究: Volagidemab (5 mg/kg,皮下注射) 在四氧嘧啶诱导的糖尿病小鼠中抑制 1 型糖尿病表型。Animal Model:Alloxan-induced diabetic mice
Dosage:5 mg/kg
Administration:Subcutaneous injection (s.c.)
Result:Reduced phosphorylated CREB protein and PEPCK protein expression to nondiabetic levels.